This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Apraclonidine hydrochloride ocular


Eye drops containing apraclonidine hydrochloride (preservative containing).

Drugs List

  • apraclonidine 5mg/ml eye drops
  • IOPIDINE 5mg/ml eye drops
  • Therapeutic Indications


    Chronic glaucoma - short-term adjunctive treatment



    Instil 1 drop into the affected eye(s) three times a day, usually for a maximum of one month.


    Children aged 12 to 18 years
    Instil 1 drop into the affected eye(s) three times a day, usually for a maximum of one month.


    Children under 12 years
    History of severe cardiovascular disorder
    History of uncontrolled cardiovascular disorder

    Precautions and Warnings

    History of vasovagal attack
    Soft contact lenses
    Cardiac failure
    Cardiovascular disorder
    Cerebrovascular disorder
    Hepatic impairment
    History of angina
    Raynaud's syndrome
    Recent myocardial infarction
    Renal impairment
    Severe ischaemic heart disease
    Thromboangiitis obliterans

    Advise ability to drive/operate machinery may be affected by side effects
    Contains benzalkonium chloride
    In combined therapy, administer eye products at least five minutes apart
    To reduce systemic absorption compress lacrimal sac during administration
    Monitor intra-ocular pressure
    Monitor patients with hepatic impairment
    Monitor patients with renal impairment
    Discontinue or interrupt treatment with acute/worsening ocular disorders
    Only recommended for short term use
    If soft contact lenses worn,insert them 15 minutes after using eye drops

    Pregnancy and Lactation


    Apraclonidine hydrochloride eye drops 5mg/ml are contraindicated in pregnancy.

    The manufacturer notes that there is little data from the use of apraclonidine hydrochloride 5mg/ml eye drops in pregnant women and that this medication is not recommended in pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Apraclonidine hydrochloride eye drops 5mg/ml are contraindicated in breastfeeding.

    The manufacturer notes that it is not known if apraclonidine is excreted in human milk when topically applied. As a risk to newborns and infants cannot be excluded, breastfeeding should be discontinued whilst taking this medication.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abnormal vision
    Blurred vision (transient)
    Chest pain
    Conjunctival follicles
    Conjunctival oedema
    Conjunctival vascular congestion
    Contact dermatitis
    Corneal erosion
    Corneal infiltrates
    Corneal staining
    Dry mouth
    Dryness and irritation of eyes
    Dryness of nasal mucosa
    Eye pain
    Eyelid erythema
    Eyelid oedema
    Eyelid reaction
    Eyelid retraction
    Eyelid scales
    Facial oedema
    Hypersensitivity reactions
    Impaired co-ordination
    Increased lacrimation
    Lid margin crusting
    Ocular discharge
    Ocular discomfort
    Ocular hyperaemia
    Ocular oedema
    Ocular pruritus
    Peripheral oedema
    Reduced visual acuity
    Sensation of foreign body in eye
    Throat irritation


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2017

    Reference Sources

    Summary of Product Characteristics: Iopidine 5mg/ml Eye Drops, Solution. Novartis Pharmaceuticals UK Ltd. Revised July 2018.

    NICE Evidence Services Available at: Last accessed: 12 July 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.